TickerFacts.

Johnson & Johnson (JNJ): Cost of Revenue

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-01-02 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$30.26B
Year ended 2025-12-28
$32.22B
Trailing 12 months to 2026-09-27
+7.1%
3-year compound annual growth
2007-12-30: $17.75B2008-12-28: $18.51B2010-01-03: $18.45B2011-01-02: $18.79B2012-01-01: $20.36B2012-12-30: $21.66B2013-12-29: $22.34B2014-12-28: $22.75B2016-01-03: $21.54B2017-01-01: $21.79B2017-12-31: $25.44B2018-12-30: $27.09B2019-12-29: $27.56B2021-01-03: $28.43B2022-01-02: $23.40B2023-01-01: $24.60B2023-12-31: $26.55B2024-12-29: $27.47B2025-12-28: $30.26B$30.26B
2007-12-30 Cost of Revenue (USD) 2025-12-28
Period endedCost of RevenueChange YoYSource filing
2025-12-28$30.26B+10.1%2026-02-11, From 2024-12-30
2024-12-29$27.47B+3.5%2026-02-11, From 2024-01-01
2023-12-31$26.55B+8.0%2026-02-11, From 2023-01-02
2023-01-01, Fiscal 2022$24.60B+5.1%2025-02-13, From 2022-01-03
2022-01-02, Fiscal 2021$23.40Bn/c2024-02-16, From 2021-01-04
2021-01-03, Fiscal 2020$28.43B+3.2%2023-02-16, From 2019-12-30
2019-12-29$27.56B+1.7%2022-02-17, From 2018-12-31
2018-12-30$27.09B+6.5%2021-02-22, From 2018-01-01
2017-12-31$25.44B+16.8%2020-02-18, From 2017-01-02
2017-01-01, Fiscal 2016$21.79B+1.2%2019-02-20, From 2016-01-04
2016-01-03, Fiscal 2015$21.54B-5.3%2018-02-21, From 2014-12-29
2014-12-28$22.75B+1.8%2017-02-27, From 2013-12-30
2013-12-29$22.34B+3.2%2016-02-24, From 2012-12-31
2012-12-30$21.66B+6.4%2015-02-24, From 2012-01-02
2012-01-01, Fiscal 2011$20.36B+8.3%2014-02-21, From 2011-01-03
2011-01-02, Fiscal 2010$18.79B+1.9%2013-02-22, From 2010-01-04
2010-01-03, Fiscal 2009$18.45B-0.3%2012-02-23, From 2008-12-29
2008-12-28$18.51B+4.3%2011-02-25, From 2007-12-31
2007-12-30$17.75Bn/a2010-03-01, From 2007-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Johnson & Johnson (JNJ)2025-12-28$30.26B+10.1%
Eli Lilly & Co (LLY)2025-12-31$11.05B+31.3%
Merck & Co., Inc. (MRK)2025-12-31$16.38B+7.8%
Pfizer Inc (PFE)2025-12-31$16.07B-10.0%
AbbVie Inc. (ABBV)2025-12-31$18.20B+7.7%
Bristol Myers Squibb Co (BMY)2025-12-31$13.94B-0.2%
Abbott Laboratories (ABT)2025-12-31$19.32B+3.3%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$8.32B-1.9%
Viatris Inc (VTRS)2025-12-31$9.29B+1.9%

Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗